Hybrid Exosome-Bilosome Oxygen Nanobubbles for Liver Fibrosis Attenuation: Antifibrotic Efficacy Investigation in Multilineage Spheroid Platform
ACS Nano Medicine · 11.11.2026 · 1 (10) · 2644-2657
DOI: 10.1021/acsnanomed.6c00127 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano Medicine, online erschienen am 30.09.2026. Verfasst von Anika Bushra und 6 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Gefördert von: NIH, NSF STTR-Phase II.
Abstract (Originalsprache)
Liver fibrosis refers to the excessive buildup of scar tissue in the liver, which can lead to cirrhosis and hepatocellular carcinoma. It often presents with a hypoxic hepatic microenvironment and elevated oxidative stress. In this work, we present a hybrid Exosome-Bilosome Oxygen-encapsulating Nanobubble (EBON) with antifibrotic properties that has the potential to protect the liver from localized hypoxia and oxidative stress-induced hepatic damage. Grapefruit-derived exosome-like vesicles utilized here may contribute to the therapeutic potential of the EBON formulation by delivering antioxidant, anti-inflammatory, and antifibrotic cargo, alongside oxygen. EBON has a sub-50 nm size with an oxygen loading capacity of about 50 mg/L and a shelf life of half a year. EBON has demonstrated excellent protection against cellular hypoxia, reactive oxygen species, and superoxide-induced damage in LX-2 and HepG2 cell lines. Additionally, EBON has shown a significant antifibrotic effect in palmitic acid and oleic acid-induced lipotoxicity and oxidative stress-mediated fibrosis model in LX-2/HepG2 multilineage hepatic spheroids. RT-qPCR results confirmed suppression of hypoxia (HIF-1α, VEGF-A), oxidative stress (Nrf2), and pro-fibrotic signaling (α-SMA, TGF-β1, and COL1A1) associated genes in the in vitro hepatic spheroid model. Additionally, the safety profile of EBON has been established in a 14-day murine oral gavage model, validating short-term oral tolerability. We propose that the hybrid Exosome-Bilosome Oxygen encapsulating Nanobubble reported here is a proof-of-concept platform with antifibrotic potential for addressing hypoxia associated with liver fibrosis.
Förderung
- NIH
- NSF STTR-Phase II
Zitieren
APA
Bushra, A., Oelze, E., Locke, T., Jayne, D., Han, X., Fan, T. M., & Irudayaraj, J. (2026). Hybrid Exosome-Bilosome Oxygen Nanobubbles for Liver Fibrosis Attenuation: Antifibrotic Efficacy Investigation in Multilineage Spheroid Platform. ACS Nano Medicine, 1(10), 2644-2657. https://doi.org/10.1021/acsnanomed.6c00127
Vancouver
Bushra A, Oelze E, Locke T, Jayne D, Han X, Fan TM, et al. Hybrid Exosome-Bilosome Oxygen Nanobubbles for Liver Fibrosis Attenuation: Antifibrotic Efficacy Investigation in Multilineage Spheroid Platform. ACS Nano Medicine. 2026;1(10):2644-2657. doi:10.1021/acsnanomed.6c00127
BibTeX
@article{Bushra2026,
author = {Bushra, Anika and Oelze, Eden and Locke, Thomas and Jayne, Dalton and Han, Xiaoxue and Fan, Timothy M. and Irudayaraj, Joseph},
title = {Hybrid Exosome-Bilosome Oxygen Nanobubbles for Liver Fibrosis Attenuation: Antifibrotic Efficacy Investigation in Multilineage Spheroid Platform},
journal = {ACS Nano Medicine},
year = {2026},
volume = {1},
number = {10},
pages = {2644--2657},
doi = {10.1021/acsnanomed.6c00127}
}
EUVIMED